File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail

TitleBCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail
Authors
Issue Date2009
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 2009, v. 15 n. 5, p. 365-373 How to Cite?
AbstractImatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, kinase domain mutations are variably resistant to second-line agents. We performed BCR-ABL kinase domain mutational studies in 25 patients in five institutions who failed imatinib and were treated with either nilotinib or dasatinib, to see if their mutational status would predict their clinical responses. Kinase domain mutations involving 11 amino acid substitutions were found in 12 (48%) patients. Most patients showed single kinase domain mutations. There was some concordance between reported drug sensitivity patterns and patient responses. Discordant responses could be related to drug dosage variations and unknown BCR-ABL independent mechanisms. The response prediction for patients with multiple kinase domain mutations was challenging and their mutational patterns could change after tyrosine kinase inhibitor therapy. Although BCR-ABL kinase domain mutational analysis has limitations as a means of predicting the clinical response to second-line tyrosine kinase inhibitors, it helps inform therapy decisions in the management of chronic myeloid leukaemia after imatinib failure.
Persistent Identifierhttp://hdl.handle.net/10722/209205
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorKwan, TK-
dc.contributor.authorMa, ESK-
dc.contributor.authorChan, YY-
dc.contributor.authorWan, TSK-
dc.contributor.authorLiu, HSY-
dc.contributor.authorSim, JPY-
dc.contributor.authorYeung, YM-
dc.contributor.authorLie, AKW-
dc.contributor.authorYip, SF-
dc.date.accessioned2015-04-09T07:57:23Z-
dc.date.available2015-04-09T07:57:23Z-
dc.date.issued2009-
dc.identifier.citationHong Kong Medical Journal, 2009, v. 15 n. 5, p. 365-373-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/209205-
dc.description.abstractImatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, kinase domain mutations are variably resistant to second-line agents. We performed BCR-ABL kinase domain mutational studies in 25 patients in five institutions who failed imatinib and were treated with either nilotinib or dasatinib, to see if their mutational status would predict their clinical responses. Kinase domain mutations involving 11 amino acid substitutions were found in 12 (48%) patients. Most patients showed single kinase domain mutations. There was some concordance between reported drug sensitivity patterns and patient responses. Discordant responses could be related to drug dosage variations and unknown BCR-ABL independent mechanisms. The response prediction for patients with multiple kinase domain mutations was challenging and their mutational patterns could change after tyrosine kinase inhibitor therapy. Although BCR-ABL kinase domain mutational analysis has limitations as a means of predicting the clinical response to second-line tyrosine kinase inhibitors, it helps inform therapy decisions in the management of chronic myeloid leukaemia after imatinib failure.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleBCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib fail-
dc.typeArticle-
dc.identifier.emailMa, ESK: eskma@hksh.com-
dc.identifier.emailWan, TSK: wantsk@HKUCC.hku.hk-
dc.identifier.emailLie, AKW: akwlie@HKUCC.hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.pmid19801694-
dc.identifier.hkuros180731-
dc.identifier.volume15-
dc.identifier.issue5-
dc.identifier.spage365-
dc.identifier.epage373-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats